Panmure Gordon downgraded shares of EKF Diagnostics (OTCMKTS:EKDHF) from a buy rating to a hold rating in a report published on Tuesday, The Fly reports.
EKDHF opened at $0.70 on Tuesday. EKF Diagnostics has a 52 week low of $0.68 and a 52 week high of $0.70.
About EKF Diagnostics
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.
See Also: What is the definition of market timing?
Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.